Lipocine Inc. (NASDAQ:LPCN) posted its quarterly earnings results on Monday. The specialty pharmaceutical company reported ($0.31) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.30) by $0.01, Bloomberg Earnings reports.

Lipocine (LPCN) traded up 0.88% during midday trading on Wednesday, reaching $4.56. The company had a trading volume of 239,960 shares. The company’s market capitalization is $87.83 million. The firm has a 50-day moving average price of $4.42 and a 200-day moving average price of $3.97. Lipocine has a 52 week low of $3.03 and a 52 week high of $5.90.

TRADEMARK VIOLATION WARNING: This story was first posted by Daily Political and is the sole property of of Daily Political. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://www.dailypolitical.com/2017/08/09/lipocine-inc-lpcn-posts-earnings-results-misses-estimates-by-0-01-eps.html.

A number of equities analysts have recently commented on LPCN shares. Roth Capital set a $38.00 price target on Lipocine and gave the stock a “buy” rating in a report on Tuesday, June 20th. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price target on shares of Lipocine in a report on Wednesday, April 26th. Finally, Canaccord Genuity set a $11.00 price target on Lipocine and gave the stock a “buy” rating in a report on Monday.

Lipocine Company Profile

Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.

Earnings History for Lipocine (NASDAQ:LPCN)

Receive News & Ratings for Lipocine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.